ZyVersa Therapeutics Reports $1.8 Million Net Loss in Q1 2026

ZyVersa Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of approximately $1.8 million, a decrease from a net loss of $2.3 million in the same period of 2025. The company has not generated any revenue to date and continues to face significant operating losses, with an accumulated deficit of about $139.4 million as of March 31, 2026. Total operating expenses for the quarter were approximately $1.3 million, down from $2.1 million in the prior year, primarily due to reduced research and development costs and lower general and administrative expenses.

The company's cash position improved, with cash and cash equivalents totaling $302,660 at the end of the first quarter, compared to $101,778 at the end of 2025. ZyVersa's total current assets increased to $742,223, up from $463,451 at the end of the previous fiscal year. However, total current liabilities also rose to $14.9 million from $12.9 million, resulting in a working capital deficit of approximately $14.1 million. The increase in liabilities was driven by higher accrued expenses and the issuance of convertible notes payable at fair value amounting to $1.2 million.

Operationally, ZyVersa has made strategic moves, including the issuance of convertible promissory notes and warrants, which provided $1 million in financing during the quarter. The company continues to focus on the development of its drug candidates, VAR 200 and IC 100, targeting chronic renal and inflammatory diseases. Research and development expenses were significantly reduced to $58,000, a 77.6% decrease from the previous year, attributed to lower payroll costs following the retirement of the Chief Medical Officer and a pause in the VAR 200 study.

Looking ahead, ZyVersa anticipates ongoing cash outflows as it continues its development activities. The company expects to incur substantial expenses related to regulatory submissions, clinical trial manufacturing, and hiring additional personnel. Management has indicated that additional financing will be necessary to support operations and development efforts, and while they believe they have access to capital resources, there is no assurance that they will secure the necessary funding on favorable terms. The company remains committed to exploring strategic partnerships and collaborations to enhance its financial position and operational capabilities.